India to Cyprus Pharmaceutical Export (2026) — $45.1M, 34 Suppliers | TransData Nexus

India to Cyprus Pharmaceutical Export (2026) — $45.1M, 34 Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — India to Cyprus

#	Formulation	Value	Share
1	Pharmaceuticals Products - Biscordex Bisoprolol USP 5 MG Tablets	$12.1M	26.7%
2	Clodor Clopidogrel Besylate 75 MG	$12.0M	26.7%
3	Ibuprofen 200mg + Methacharbamol 500mg Tablet	$5.1M	11.3%
4	Bisoprolol BP 5mg + Hydrochlorthiazide 12.5mg Tabl	$2.7M	6.0%
5	Posaconazole 100mg Gr Tablets. Batch No.	$2.3M	5.1%
6	Bisoprolol BP 10 MG Tablet	$1.6M	3.5%
7	Glimepiride BP 1 MG Tablet	$1.4M	3.1%
8	Posaconazole 100mg Gastro Resistant Tablets/posaconazole Delayed Release Tablet…	$1.2M	2.7%
9	Posaconazole 100mg Gr Tablets (985386 Packs)kgs	$780.1K	1.7%
10	Posaconazole 100 MG Gastro Resistant Tablets Batch : Cm108, Cm109, Cm110, Cm111	$384.5K	0.9%
11	Posaconazole 100mg Gastro Resistant Tablets, Batch No.cm045,cm046,cm047,cm048 5…	$366.5K	0.8%
12	Posaconazole 100mg Gr Tablets, Batch -cl070, Cl071, Cl072, (426708 Tablets )	$282.6K	0.6%
13	Omeprazole Pellets 8.5%	$216.5K	0.5%
14	Posaconazole 100mg Gr Tablets, Batch -cl073, Cl074 (283998 Tablets )	$188.1K	0.4%
15	Posaconazole 100mg Gr Tablets Batch No.cl148 and Cl164 (285.060 Tablets)	$185.4K	0.4%

India exports 18+ pharmaceutical formulations to Cyprus with a combined trade value of $45.1M. Key products include Clopidogrel ($12.0M), Ibuprofen ($5.1M), Bisoprolol ($2.7M), Posaconazole ($2.3M), Glimepiride ($1.4M). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 309 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — India to Cyprus Trade Routes

1Clopidogrel$12.0M

2Ibuprofen$5.1M

3Bisoprolol$2.7M 4Posaconazole$2.3M 5Glimepiride

Top Indian Exporters to Cyprus

1Fredun Pharmaceuticals Ltd

$35.0M

2Aet Laboratories Private Limited

$8.3M

3Cipla Limited

$865K

4Indoco Remedies Limited

$380K

5M/s. Asha Ganga Exports

Port Analysis — India to Cyprus Pharmaceutical Shipments

Indian Export Ports

HAZIRA PORT SURAT ICD0.3%

GURGAON ICD/ GARI HARSARU ICD0.3%

SAHAR AIR29.8%

BANGALORE ACC (INBLR4)7.1%

BANGALORE AIR22.7%

Cyprus Import Ports

LARNACA84.1%

LIMASSOL3.9%

Limassol1.6%

EL ENCANTO0.6%

ERCAN3.2%

Trade Statistics

Total Value$45.1M

Shipments309

Indian Exporters34

Cyprus Buyers44

Avg Shipment$146K

Products210

Other Destinations

United States$8.8B United Kingdom$1.2B Canada$1.1B France

Last updated: March 28, 2026

India–Cyprus Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The pharmaceutical trade between India and Cyprus has experienced notable growth over the past decade. In 2024, India's pharmaceutical exports to Cyprus were valued at approximately $5.9 million, marking a significant increase from previous years. This upward trajectory reflects the strengthening bilateral relations and the expanding demand for Indian pharmaceutical products in the Cypriot market.

Key milestones in this trade relationship include the establishment of direct shipping routes and the recognition of Indian manufacturing facilities by Cypriot authorities. These developments have facilitated smoother logistics and enhanced the credibility of Indian pharmaceutical products in Cyprus. The consistent growth underscores the strategic importance of this corridor for both nations, with India leveraging its robust pharmaceutical manufacturing capabilities to meet the needs of the Cypriot market.

2India's Market Position

India holds a significant position in Cyprus's pharmaceutical import landscape. In 2024, India's pharmaceutical exports to Cyprus were valued at $5.9 million, contributing to a total of $88.75 million in exports from India to Cyprus. This positions India as a key supplier, reflecting its competitive edge in the global pharmaceutical market.

Strategically, India's extensive experience in pharmaceutical manufacturing, adherence to international quality standards, and cost-effective production processes make it a preferred partner for Cyprus. The alignment of India's export capabilities with Cyprus's healthcare requirements further solidifies this market position.

Cyprus Regulatory Landscape for Indian Pharmaceutical Exports

Registration process, GMP requirements, import documentation

1Registration Process

Indian pharmaceutical companies seeking to register products in Cyprus must navigate a structured process overseen by the Cypriot Ministry of Health's Pharmaceutical Services. The registration involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy. This dossier must be accompanied by a written confirmation from the Indian regulatory authority, the Central Drugs Standard Control Organisation (CDSCO), affirming that the manufacturing site adheres to GMP standards equivalent to those in the EU. (ema.europa.eu)

The evaluation process is rigorous, with timelines varying based on the product type and the completeness of the submitted documentation. Typically, the review period ranges from six months to a year. It's imperative for Indian exporters to ensure that all documentation is accurate and complete to facilitate a smooth registration process.

2GMP & Facility Requirements

Cyprus, as an EU member state, requires that pharmaceutical products imported from third countries, including India, be manufactured in facilities that comply with EU GMP standards. The EMA's guidelines stipulate that all active substances imported into the EU must be accompanied by a written confirmation from the exporting country's competent authority, in this case, the CDSCO, confirming that the manufacturing site adheres to GMP standards equivalent to those in the EU. (ema.europa.eu)

The inspection process involves periodic audits by Cypriot authorities to verify compliance with GMP standards. Mutual recognition agreements between the EMA and the CDSCO facilitate this process, allowing for the acceptance of inspections and certifications across jurisdictions. Indian manufacturers are encouraged to maintain high-quality standards and keep abreast of any changes in EU regulations to ensure continued market access.

3Import Documentation

Importing pharmaceutical products into Cyprus requires adherence to specific documentation and customs procedures. Key documents include the Certificate of Pharmaceutical Product (CPP), Certificate of Analysis (CoA), and proof of GMP compliance. These documents must be submitted to the Cypriot Ministry of Health's Pharmaceutical Services for verification. (moh.gov.cy)

Customs procedures involve the submission of a customs declaration, accompanied by the aforementioned documents, to the Cyprus Customs and Excise Department. The customs authorities will assess the documentation and may conduct inspections to ensure compliance with Cypriot and EU regulations. It's essential for Indian exporters to ensure that all documentation is accurate and complete to facilitate a smooth import process.

TransData Nexus Research · Cyprus regulatory databasesMar 2026

Product Categories & Therapeutic Trends — India to Cyprus

Dominant categories, emerging opportunities, and demand drivers

1Dominant Categories

The dominant therapeutic areas in India's pharmaceutical exports to Cyprus include cardiovascular and anti-infective medications. Products such as Bisoprolol USP 5 mg tablets and Clopidogrel Besylate 75 mg tablets are among the top exports, indicating a strong demand for cardiovascular treatments in Cyprus. This aligns with the global trend of increasing cardiovascular disease prevalence and the need for effective management solutions.

The demand for anti-infective agents, including Posaconazole 100 mg gastro-resistant tablets, reflects the ongoing need for antifungal treatments in the region. These trends suggest that Indian pharmaceutical exporters should continue to focus on these therapeutic areas to meet the evolving healthcare needs of the Cypriot population.

2Emerging Opportunities

The expiration of patents for several blockbuster drugs presents opportunities for Indian pharmaceutical companies to introduce generic versions into the Cypriot market. Additionally, the increasing demand for biosimilars in Europe offers a potential growth area for Indian exporters. Cyprus's healthcare system, which is integrated with the EU, provides a platform for Indian companies to introduce innovative therapeutic solutions.

Furthermore, the rising prevalence of chronic diseases in Cyprus creates a demand for long-term treatment options, presenting an opportunity for Indian exporters to supply cost-effective and high-quality pharmaceutical products.

3Demand Drivers

Cyprus's aging population and the increasing prevalence of chronic diseases, such as cardiovascular conditions and diabetes, are significant drivers of pharmaceutical import demand. The Cypriot government's focus on enhancing healthcare infrastructure and expanding insurance coverage further stimulates the need for a diverse range of pharmaceutical products. These factors contribute to a growing market for imported medicines, particularly those that offer therapeutic efficacy and cost-effectiveness.

TransData Nexus Research · DGFT trade data analysisMar 2026

FAQ — India to Cyprus Pharmaceutical Trade

What is the total value of India's pharmaceutical export to Cyprus?

India exported pharmaceuticals worth $45.1M to Cyprus across 309 verified shipments.

Who are the top Indian pharmaceutical exporters to Cyprus?

1. FREDUN PHARMACEUTICALS LTD — $35.0M. 2. AET LABORATORIES PRIVATE LIMITED — $8.3M. 3. CIPLA LIMITED — $864.8K. Total: 34 suppliers.

Which companies in Cyprus import pharmaceuticals from India?

1. N.V.O WAREHOUSING & LOGISTICS LTD — $34.9M. 2. DELORBIS PHARMACEUTICALS LTD — $4.4M. 3. M/S. DELORBIS PHARMACEUTICALS LTD. — $2.1M. 44 buyers total.

What pharmaceutical products does India export most to Cyprus?

1. Pharmaceuticals Products - Biscordex Bisoprolol USP 5 MG Tablets ($12.1M, 26.7%); 2. Clodor Clopidogrel Besylate 75 MG ($12.0M, 26.7%); 3. Ibuprofen 200mg + Methacharbamol 500mg Tablet ($5.1M, 11.3%); 4. Bisoprolol BP 5mg + Hydrochlorthiazide 12.5mg Tabl ($2.7M, 6.0%); 5. Posaconazole 100mg Gr Tablets. Batch No. ($2.3M, 5.1%)

Which ports handle pharmaceutical shipments from India to Cyprus?

Export: HAZIRA PORT SURAT ICD, GURGAON ICD/ GARI HARSARU ICD, SAHAR AIR, BANGALORE ACC (INBLR4), BANGALORE AIR. Import: LARNACA, LIMASSOL, Limassol, EL ENCANTO, ERCAN.

Why does Cyprus import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $45.1M corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply Cyprus?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to Cyprus pharmaceutical trade?

$146.1K per consignment across 309 shipments.

How many Indian pharmaceutical companies export to Cyprus?

34 Indian companies. Largest: FREDUN PHARMACEUTICALS LTD with $35.0M.

How can I find verified Indian pharmaceutical suppliers for Cyprus?

TransData Nexus covers 34 active exporters with shipment history and trade values at transdatanexus.com.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to Cyprus identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 309 verified shipments from 34 Indian exporters to 44 Cyprus buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

34 Exporters

44 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

India to Cyprus Pharmaceutical Export